A CRO & IRB PERSPECTIVE

Diversity in clinical research is imperative to ensure the safety and effectiveness of drugs and medical devices for all people—and everyone in the industry is a key stakeholder. Clinical trials today still lack ethnic diversity, and to make trials more inclusive and improve equity in research, we ALL have a part to play.

TransPerfect Life Sciences’ webinar series will take a closer look into each stakeholder’s role, current challenges, misconceptions, and activities for more inclusive clinical trials.  

In the first webinar in the series, Amanda Ryan, President of G3 Life Sciences, will speak with Aman Khera, VP, Global Head of Regulatory Strategy at Worldwide Clinical Trials, and Luke Gelinas, Advarra’s IRB Chair and Senior Advisor, about their perspective on diversity in clinical trials. They will discuss the role language services and cultural competency play in creating greater access to information for patients, as well as how more robust payment practices and decentralized clinical trials can further diversify the patient population.

Written by: Mark Wade, Global Practice Leader, TransPerfect Life Sciences

The debate surrounding best practices for patient management and data collection during clinical trials is ongoing.

What is the best process? How do sponsors get the best results? Which method garners the highest quality data while reducing timelines and costs?

In our latest whitepaper “The Tale of Two Trials,” we re-explore the benefits and drawbacks of the traditional, paper-based outcomes assessment method, as well as the advantages of the emerging electronic clinical outcomes assessment (eCOA) solutions. With each having the potential to affect data quality, timelines, and overall trial cost, the choice between them is a much discussed topic.

Patients are, at last, gaining a voice in healthcare. Stakeholders have come to recognize that patients have valuable information to share about their experiences with diseases and medications that should influence policy and treatment decisions.

The U.S. Food & Drug Administration (FDA), for example, has launched an initiative, “The Voice of the Patient,” to gather patient perspectives across specific disease areas. Information reported by clinical trial participants on their symptoms and health practices is increasingly important to the success of studies proving the safety and efficacy of investigational drugs...

Written by: Mark Wade, Global Practice Leader, TransPerfect Life Sciences

The rush to a vaccine has accelerated an already dynamic research process. This has led to many innovations and an evolution of procedures. The language translation industry has seen enormous stressors and has had to create and modify processes and technologies similarly.

The pandemic has changed society profoundly. The disruption in human and business interactions have not only affected the travel, conference, and hospitality industries but has also changed the clinical research landscape forever.

In this new white paper, Mark Wade shares how new processes and technologies are enabling higher quality translations for clinical research amid the race to a vaccine.

In order to ensure a fluid experience for a patient, usability testing is a critical data point to consider. Addressing both a patient’s needs and access to a digital platform is key to data collection.

TransPerfect, along with our partners from Parexel, Clinical Ink, and Health Psychology Research, recently published a poster at the Virtual ISPOR Europe 2020 conference that reviews the impact of moving from in-person to electronic data collection.